Skip to main navigation Skip to search Skip to main content

DrugDL: dual-modal deep learning framework for multi-property drug prediction and targeted therapy discovery

  • Qi Zhang (Co-first Author)
  • , Xuan Yu (Co-first Author)
  • , Yuxiao Wei (Co-first Author)
  • , Yunpeng Xia
  • , Long-Chen Shen
  • , Zhi-Hui Wang
  • , Hong-Bin Shen
  • , Dong-Jun Yu*
  • *Corresponding author for this work

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

3 Downloads (CityUHK Scholars)

Abstract

Motivation: The accurate and robust representation of drug molecule features, the prediction of drug-target biomacromolecule interactions, and the determination of physicochemical properties are crucial in drug development. However, these tasks remain challenging due to issues such as the limited generalizability of single-modal representations, the absence of multitask prediction frameworks, and weak adaptability in cold-start scenarios. Results: In this study, we present DrugDL, a framework for comprehensive drug molecule representation and the prediction of multiple downstream tasks, including drug-target interactions, binding affinities, binding sites, physicochemical properties, toxicity, and drug–drug interactions. DrugDL jointly learns representations of the drug chemical space and the target protein biological space, while capturing multiscale interaction mechanisms between drug molecules and target proteins through the integration of cross-modal contrastive learning and single-modal feature enhancement algorithms. Specifically, DrugDL employs a multitask prediction framework to predict multiple properties of drug molecules. In practical applications, it consistently outperforms state-of-the-art methods, particularly in cold-start tasks. The framework has been successfully applied to high-throughput screening, the identification of inhibitors of SARS-CoV-2 and metabolic enzymes, and the prediction of cancer-targeted drugs. Experimental validations on EGFR and ALK targets further demonstrate its effectiveness as a precise drug discovery tool. By enabling accurate molecular representation and multi-property prediction, DrugDL provides end-to-end technical support for drug development, thereby significantly accelerating the drug discovery process. Availability and implementation: The datasets and code are available at https://github.com/ZhangQi9910/DrugDL. The version of record is archived in Zenodo with the DOI: 10.5281/zenodo.20579718. © The Author(s) 2026. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Original languageEnglish
Article numberbtag392
Number of pages16
JournalBioinformatics
Volume42
Issue number7
Online published15 Jun 2026
DOIs
Publication statusPublished - Jul 2026

Funding

This work was supported by the National Natural Science Foundation of China (62372234, 62072243) and the Natural Science Foundation of Jiangsu (BK20201304).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Publisher's Copyright Statement

  • This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/

Fingerprint

Dive into the research topics of 'DrugDL: dual-modal deep learning framework for multi-property drug prediction and targeted therapy discovery'. Together they form a unique fingerprint.

Cite this